Abstract
Inflammatory activation, a major driver of preterm birth and subsequent neonatal morbidity, is an attractive pharmacological target for new preterm birth therapeutics. Inflammation elicited by intraamniotic infection is causally associated with preterm birth, particularly in infants delivered ≤34 weeks’ gestation. However, sterile triggers of PTB, including placental ischaemic injury, uterine distention, cervical disease, or imbalance in the immune response, also act through inflammatory mediators released in response to tissue damage. Toll-like Receptors (TLRs) are critical upstream gate-keepers controlling the inflammatory activation that precedes preterm delivery, as well as in normal term labour. In particular, TLR4 is implicated for its capacity to sense and integrate a range of disparate infectious and sterile pro-inflammatory triggers, and so acts as a point-ofconvergence through which a range of infectious and sterile agents can activate and accelerate the parturition cascade. Recent studies point to the TLR4 signalling complex as a tractable target for the inhibition of fetal, placental & intraamniotic inflammatory cytokine production. Moreover, studies on mice show that novel small molecule antagonists of TLR4 signalling are highly effective in preventing preterm birth induced by bacterial mimetic LPS, heat-killed E. coli or the TLR4-dependent pro-inflammatory lipid, Platelet Activating Factor (PAF). In this review, we discuss the role of TLR4 in regulating the timing of birth and the potential utility of TLR4 antagonists as novel therapeutics for preterm delivery.
Keywords: Cytokines, inflammation, pregnancy, parturition, toll-like receptor 4.
Current Pharmaceutical Design
Title:Toll-like Receptor-4: A New Target for Preterm Labour Pharmacotherapies?
Volume: 24 Issue: 9
Author(s): Sarah A. Robertson*, Hanan H. Wahid, Peck Yin Chin, Mark R. Hutchinson, Lachlan M. Moldenhauer and Jeffrey A. Keelan
Affiliation:
- Robinson Research Institute and Adelaide Medical School, University of Adelaide, Adelaide SA 5005,Australia
Keywords: Cytokines, inflammation, pregnancy, parturition, toll-like receptor 4.
Abstract: Inflammatory activation, a major driver of preterm birth and subsequent neonatal morbidity, is an attractive pharmacological target for new preterm birth therapeutics. Inflammation elicited by intraamniotic infection is causally associated with preterm birth, particularly in infants delivered ≤34 weeks’ gestation. However, sterile triggers of PTB, including placental ischaemic injury, uterine distention, cervical disease, or imbalance in the immune response, also act through inflammatory mediators released in response to tissue damage. Toll-like Receptors (TLRs) are critical upstream gate-keepers controlling the inflammatory activation that precedes preterm delivery, as well as in normal term labour. In particular, TLR4 is implicated for its capacity to sense and integrate a range of disparate infectious and sterile pro-inflammatory triggers, and so acts as a point-ofconvergence through which a range of infectious and sterile agents can activate and accelerate the parturition cascade. Recent studies point to the TLR4 signalling complex as a tractable target for the inhibition of fetal, placental & intraamniotic inflammatory cytokine production. Moreover, studies on mice show that novel small molecule antagonists of TLR4 signalling are highly effective in preventing preterm birth induced by bacterial mimetic LPS, heat-killed E. coli or the TLR4-dependent pro-inflammatory lipid, Platelet Activating Factor (PAF). In this review, we discuss the role of TLR4 in regulating the timing of birth and the potential utility of TLR4 antagonists as novel therapeutics for preterm delivery.
Export Options
About this article
Cite this article as:
Robertson A. Sarah*, Wahid H. Hanan , Chin Yin Peck , Hutchinson R. Mark, Moldenhauer M. Lachlan and Keelan A. Jeffrey , Toll-like Receptor-4: A New Target for Preterm Labour Pharmacotherapies?, Current Pharmaceutical Design 2018; 24 (9) . https://dx.doi.org/10.2174/1381612824666180130122450
DOI https://dx.doi.org/10.2174/1381612824666180130122450 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Wound Healing: What Happens in Microgravity?
Current Biotechnology Immunomodulatory Therapies for Renal Cell Carcinoma
Protein & Peptide Letters Current State of Bioabsorbable Polymer-Coated Drug-Eluting Stents
Current Cardiology Reviews Effect of Probenecid on the Pain-Related Behaviour and Morphological Markers in Orofacial Formalin Test of the Rat
CNS & Neurological Disorders - Drug Targets Comprehensive Evaluation and Clinical Application of Combined Redox Assay Methods to Determine Total Antioxidant Capacity
Current Analytical Chemistry Kinases as Targets for Parkinson's Disease: From Genetics to Therapy
CNS & Neurological Disorders - Drug Targets The Lord of the Bacteria: The Fellowship of the Leader and Other Serine Protease Inhibitors
Current Pharmaceutical Design Acute Tonsillitis
Infectious Disorders - Drug Targets Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Development of Peptide Inhibitors to Block Type I and Type III Collagen-platelet Interaction
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Mechanisms and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry Emerging Anti-inflammatory Therapies for Atherosclerosis
Current Pharmaceutical Design Targeting Hypertension: Superoxide Anions are Involved in Apelin-induced Long-term High Blood Pressure and Sympathetic Activity in the Paraventricular Nucleus
Current Neurovascular Research The Therapeutic Potential of RNA Interference: Novel Approaches for Cancer Treatment
Current Pharmaceutical Biotechnology Toxicity of Nanoparticles
Current Medicinal Chemistry Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Current Topics in Medicinal Chemistry Radiation-Induced Stress Proteins - the Role of Heat Shock Proteins (HSP) in Anti- Tumor Responses
Current Medicinal Chemistry Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials